Greenearth Energy Ltd

GER Details
Appointed as an Accredited Partner of independent energy expert, Verdia: Greenearth Energy Ltd (ASX: GER) recently reported that the number of unlisted options currently on issue is 47, 550,000 (as on November 07, 2016). The group has announced that NewCO2Fuels Ltd (NCF, formed with the support of GER) has entered into terms with Sinopec Engineering (Group) Co Ltd (SEG) to commercialize NCF’s CO2-to-fuel technology for the Chinese market. Moreover, GER has confirmed that it’s Vivid Industrial and Ilum?a?Lite intelligent lighting business has been appointed as an Accredited Partner of independent energy expert, Verdia. Verdia manages Westpac’s Energy Efficient Financing Program that is supported by $200 million from the Clean Energy Finance Corporation. On the other hand, GER stock fell over 21.25% in the last three months (as of November 04, 2016) due to weakening sentiment given the rising expenses. We believe that the stock is “Expensive” at the current price of – $ 0.061
 

GER Daily Chart (Source: Thomson Reuters) 

Eden Innovations Ltd (Eden Energy Ltd)

EDE Details
Rebranding and capital raising efforts: Eden Energy Ltd (ASX: EDE) has recently changed the name to Eden Innovations Ltd as passed in its latest AGM. The group expects the cash outflows for the December quarter to be $A 2100,000. The expansion of EDE’s Colorado based production capability of EdenCrete™ to a targeted maximum of 2 million - 2.4 million gallons per year is on schedule to be operational later in first quarter of 2017. Georgia Department of Transportation (GDOT) has proposed to use EdenCrete™ in several state funded forthcoming highway slab replacement projects in Georgia. The group has also completed the purchase of Denver premises for USD 1.2 million payable over five years. EDE has placed A$15 million additional capital through Bell Potter.
 

US Production Scale-up (Source: Company Reports)
 
Recently, the group issued to 33,333,333 fully paid ordinary shares to investors. Moreover, US commercial trials have now started and more than 20 trials are underway or scheduled across USA during 2016 for many possible applications and trials. But any negative results of these trials could hurt the stock sentiment further. EDE stock fell over 26.32% in the last six months (as of November 02, 2016) and still we give an “Expensive” recommendation on the stock at the current price of – $ 0.205
 

EDE Daily Chart (Source: Thomson Reuters)

Disclaimer
 
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376).The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd currently hold positions in:  BHP, BKY, KCN, PDN, and RIO. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.